Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.3478
+0.0327 (10.38%)
At close: Jun 30, 2025, 4:00 PM
0.3209
-0.0269 (-7.73%)
After-hours: Jun 30, 2025, 7:59 PM EDT
Plus Therapeutics Employees
Plus Therapeutics had 21 employees as of December 31, 2024. The number of employees increased by 1 or 5.00% compared to the previous year.
Employees
21
Change (1Y)
1
Growth (1Y)
5.00%
Revenue / Employee
$247,905
Profits / Employee
-$1,291,333
Market Cap
17.74M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
PSTV News
- 18 hours ago - Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - GlobeNewsWire
- 4 days ago - Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary - GlobeNewsWire
- 5 days ago - Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET - GlobeNewsWire
- 5 days ago - Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer - GlobeNewsWire
- 6 days ago - Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q - GlobeNewsWire
- 6 weeks ago - Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) - GlobeNewsWire